Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)
NCT ID: NCT06012279
Last Updated: 2024-02-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
117 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-08-01
Study Completion Date
2024-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to evaluate the short-term clinical outcomes of starting Dapagliflozin on the same day of hospital admission in patients with acute decompensated heart failure (ADHF) with reduced ejection fraction.
The main questions it aims to answer are:
* Does early initiation of Dapagliflozin improve the length of hospital stay and in-hospital mortality in patients with ADHF?
* Does early initiation of Dapagliflozin enhance the diuretic response, weight reduction and pro-BNP reduction in the acute stage of HF?
* Does early initiation of Dapagliflozin adversely affect the hemodynamic stability and kidney functions in the acute stage of HF?
Participants will be randomized with the ratio of 1:1 within 24 hours of admission to receive Dapagliflozin 10 mg/day versus standard of care. Follow up will continue for 2 months after hospital discharge.
Researchers will compare the in-hospital and 60-day clinical outcomes in the Dapagliflozin group versus the standard treatment group.
The main questions it aims to answer are:
* Does early initiation of Dapagliflozin improve the length of hospital stay and in-hospital mortality in patients with ADHF?
* Does early initiation of Dapagliflozin enhance the diuretic response, weight reduction and pro-BNP reduction in the acute stage of HF?
* Does early initiation of Dapagliflozin adversely affect the hemodynamic stability and kidney functions in the acute stage of HF?
Participants will be randomized with the ratio of 1:1 within 24 hours of admission to receive Dapagliflozin 10 mg/day versus standard of care. Follow up will continue for 2 months after hospital discharge.
Researchers will compare the in-hospital and 60-day clinical outcomes in the Dapagliflozin group versus the standard treatment group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
NCT04298229
Heart Failure
Diabetes Mellitus, Type 2
COMPLETED
PHASE3
Dapa Acute Heart Failure Study
NCT05759000
Heart Failure
RECRUITING
The Effect of Dapagliflozin on Patients With Cardiomyopathy
NCT07076615
Acute Decompensated Heart Failure (ADHF)
RECRUITING
PHASE4
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
NCT06535529
Acute Decompensated Heart Failure
RECRUITING
PHASE3
Dapagliflozin in the Treatment of Heart Failure
NCT05727423
Heart Failure
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background and Rationale:
With growing interest in studying the pharmacodynamics of SGLT-2 inhibitors, several cardio-protective mechanisms were defined beyond their diuretic effect. Those included anti-inflammatory effect and attenuation of oxidative stress in myocardial cells, renin-angiotensin aldosterone system blocking via activating AT-2 receptors, inhibition of Na+-H+ exchanger within myocardial cells , improving cardiac metabolomics via supplying more ketones , and weight reduction through lowering insulin secretion.
These findings invited more research to evaluate their benefit in patients having heart failure with reduced ejection fraction (HFrEF) regardless of diabetes mellitus (DM) status. Two large trials (DAPA-HF and EMPEROR-Reduced) have shown a consistent mortality benefit for SGLT-2 inhibitors in HFrEF patients in absence of DM.
Having a wide safety margin and low risk of complications, the use of SGLT-2 inhibitors was recently extended beyond the scope of cardiovascular disease to include patients with chronic kidney disease after their renal protective role was validated in CREDENCE and DAPA-CKD trials with significantly lower risk of albuminuria and disease progression.
Since most of the forementioned studies included patients with chronic HF who are stable on oral therapy, it has become urging to study the efficacy and safety of starting SGLT-2 inhibitors in patients with acute HF during the hospital phase. Ongoing trials have been investigating this issue recently, with pending outcomes. However, patients with de-novo AHF secondary to acute coronary syndrome have been excluded from these studies. Also, some of those studies started SGLT2 inhibitors only after stabilization of acute heart failure patients in-hospital.
Objectives:
The aim of this study is to evaluate the immediate and short-term clinical outcomes of starting Dapagliflozin in patients with acute decompensated heart failure with reduced ejection fraction during hospitalization.
Study Methods
* Population of study: Patients admitted to hospital with acute heart failure, either de-novo or acute decompensated on top of chronic.
* Study location: Kasr Al-Ainy Medical School, Cairo university.
* Recruitment location: Kasr Al-Ainy Medical School, Aswan Heart Centre.
* Methodology in details:
A-Full medical history including:
Age, gender, onset and duration of shortness of breath and NYHA functional class. Past history of DM, HTN, CAD, VHD, HF, stroke, other comorbidities, and smoking status will be obtained in all participants.
B-Full clinical examination including:
Assessment of body weight, height and calculation of BMI and BSA. Vital signs including blood pressure measurement using standard technique, assessment of the pulse, respiratory rate and temperature. Examination of all body systems.
C- Blood sample and chemistry:
Blood tests will be done to all participants. Lab workup will include CBC, liver and kidney function tests, electrolytes, HBA1C and lipid profile. Estimated GFR will be calculated using CKD-EPI equation.
D- Serum NT-proBNP:
On admission and on day 4 (or at discharge if earlier).
E- Electrocardiography (ECG):
12-lead ECG will be done for all participants. Data will be recorded including rhythm, ST-T changes, QRS width, and any form of conduction disturbance.
F- Conventional Transthoracic echocardiography (TTE):
TTE will be done for all patients on admission:
* Measure LV end-systolic and end-diastolic diameters.
* Measure LV systolic function by M-mode and Biplane Simpson's method.
* Measure LV diastolic function, E/A and E/e' ratio
* Calculate LA volume index.
* Calculate LV mass index.
* Assess cardiac valves (mitral, aortic and tricuspid valves).
* Estimate systolic pulmonary artery pressure.
* Measure RV dimensions and function.
* Measure RA area.
G. 2D-Speckle tracking echocardiography:
• Measure LV global longitudinal strain (GLS).
H. Randomization:
* Patients will be randomized with the ratio of 1:1 within 24 hours of admission to receive Dapagliflozin 10 mg/day versus standard of care (using online randomization https://en.calc-site.com/randoms/grouping). Treatment will continue for 2 months after discharge.
* Randomized treatment will be withheld in case of hypotension (SBP\<90 mmHg), development of hypoglycemia \< 80 mg/dl, metabolic acidosis, or \>50% drop in eGFR for 2 consecutive measures.
* Randomized treatment will be resumed after resolution of the previously mentioned conditions.
I. Hospital course:
* Daily vital signs and assessment of fluid status.
* Daily fluid balance.
* Body weight change after 4 days of hospital admission or less if discharged earlier.
* Response to diuretics defined as adjusted urine output and adjusted weight change per 40 mg of IV furosemide or equivalent dose.
* Daily urea, creatinine and eGFR.
* Blood sugar monitoring.
J. Follow-up visits:
Patients will be followed in the outpatient clinic at 2 months after discharge, with the following data to be obtained:
1. NYHA class, and occurrence of any cardiac symptoms.
2. Need and reason for re-hospitalization.
3. History of dysuria, or genital discharge.
4. Medication intake and compliance.
5. Clinical examination including vital signs, body weight, and signs of left or right side HF.
6. Urea, creatinine and eGFR.
7. Electrolytes including Na and K.
8. HbA1C.
K. Follow-up serum NT-proBNP:
* At 2 months after discharge.
* Data will be compared to baseline values.
In case of mortality, data will be collected about the date and cause of mortality, and any reported clinical events before mortality.
* Potential risks:
1. Mild pain during blood sample withdrawal.
2. Low incidence of occurrence of side effects for Dapagliflozin including urinary tract infection, hypotension, and in rare cases hypoglycemia or metabolic acidosis.
* Confidentiality of data:
Data will be presented and used without inference to the name or personal data of the patients. All patient records will be handelled in accordance to hospital and national confidentiality protocols.
\- Sample size :
Based on the results mentioned in a previously published similar study, where the frequency of composite endpoint of worsening HF, rehospitalization for HF or death at 60 days was 10% in the Empagliflozin group versus 33% in the placebo group, with a study power of 80% and a significance level of 5%, and by using an online sample size calculator (http://statulator.com/SampleSize/ss2P.html), the estimated sample size is 55 patients per group.
\- Statistical analysis
Descriptive statistics will be summarized as mean ± SD for normally distributed continuous variables or otherwise as median and 25th to 75th percentile. Categorical variables will be described by frequencies and percentages. Differences in paired samples will be tested using the Wilcoxon signed-rank test or paired Student's t-test. Categorical variables will be compared using the chi-square or Fisher's exact test. Statistical significance is defined at a level of α ≤ 0.05.
Kaplan-Meier survival curves will be drawn to assess differences between groups for the time to an event. For the Cox model, univariate analysis of each of the possible predictors of the outcome will be tested, and only those variables that are significant at P\<0.05 will be included in a multivariable model. A stepwise option will be used to determine independent predictors of the outcome variables.
Analysis will be performed with SPSS, Version 24 (SPSS Inc., Chicago, IL, USA).
With growing interest in studying the pharmacodynamics of SGLT-2 inhibitors, several cardio-protective mechanisms were defined beyond their diuretic effect. Those included anti-inflammatory effect and attenuation of oxidative stress in myocardial cells, renin-angiotensin aldosterone system blocking via activating AT-2 receptors, inhibition of Na+-H+ exchanger within myocardial cells , improving cardiac metabolomics via supplying more ketones , and weight reduction through lowering insulin secretion.
These findings invited more research to evaluate their benefit in patients having heart failure with reduced ejection fraction (HFrEF) regardless of diabetes mellitus (DM) status. Two large trials (DAPA-HF and EMPEROR-Reduced) have shown a consistent mortality benefit for SGLT-2 inhibitors in HFrEF patients in absence of DM.
Having a wide safety margin and low risk of complications, the use of SGLT-2 inhibitors was recently extended beyond the scope of cardiovascular disease to include patients with chronic kidney disease after their renal protective role was validated in CREDENCE and DAPA-CKD trials with significantly lower risk of albuminuria and disease progression.
Since most of the forementioned studies included patients with chronic HF who are stable on oral therapy, it has become urging to study the efficacy and safety of starting SGLT-2 inhibitors in patients with acute HF during the hospital phase. Ongoing trials have been investigating this issue recently, with pending outcomes. However, patients with de-novo AHF secondary to acute coronary syndrome have been excluded from these studies. Also, some of those studies started SGLT2 inhibitors only after stabilization of acute heart failure patients in-hospital.
Objectives:
The aim of this study is to evaluate the immediate and short-term clinical outcomes of starting Dapagliflozin in patients with acute decompensated heart failure with reduced ejection fraction during hospitalization.
Study Methods
* Population of study: Patients admitted to hospital with acute heart failure, either de-novo or acute decompensated on top of chronic.
* Study location: Kasr Al-Ainy Medical School, Cairo university.
* Recruitment location: Kasr Al-Ainy Medical School, Aswan Heart Centre.
* Methodology in details:
A-Full medical history including:
Age, gender, onset and duration of shortness of breath and NYHA functional class. Past history of DM, HTN, CAD, VHD, HF, stroke, other comorbidities, and smoking status will be obtained in all participants.
B-Full clinical examination including:
Assessment of body weight, height and calculation of BMI and BSA. Vital signs including blood pressure measurement using standard technique, assessment of the pulse, respiratory rate and temperature. Examination of all body systems.
C- Blood sample and chemistry:
Blood tests will be done to all participants. Lab workup will include CBC, liver and kidney function tests, electrolytes, HBA1C and lipid profile. Estimated GFR will be calculated using CKD-EPI equation.
D- Serum NT-proBNP:
On admission and on day 4 (or at discharge if earlier).
E- Electrocardiography (ECG):
12-lead ECG will be done for all participants. Data will be recorded including rhythm, ST-T changes, QRS width, and any form of conduction disturbance.
F- Conventional Transthoracic echocardiography (TTE):
TTE will be done for all patients on admission:
* Measure LV end-systolic and end-diastolic diameters.
* Measure LV systolic function by M-mode and Biplane Simpson's method.
* Measure LV diastolic function, E/A and E/e' ratio
* Calculate LA volume index.
* Calculate LV mass index.
* Assess cardiac valves (mitral, aortic and tricuspid valves).
* Estimate systolic pulmonary artery pressure.
* Measure RV dimensions and function.
* Measure RA area.
G. 2D-Speckle tracking echocardiography:
• Measure LV global longitudinal strain (GLS).
H. Randomization:
* Patients will be randomized with the ratio of 1:1 within 24 hours of admission to receive Dapagliflozin 10 mg/day versus standard of care (using online randomization https://en.calc-site.com/randoms/grouping). Treatment will continue for 2 months after discharge.
* Randomized treatment will be withheld in case of hypotension (SBP\<90 mmHg), development of hypoglycemia \< 80 mg/dl, metabolic acidosis, or \>50% drop in eGFR for 2 consecutive measures.
* Randomized treatment will be resumed after resolution of the previously mentioned conditions.
I. Hospital course:
* Daily vital signs and assessment of fluid status.
* Daily fluid balance.
* Body weight change after 4 days of hospital admission or less if discharged earlier.
* Response to diuretics defined as adjusted urine output and adjusted weight change per 40 mg of IV furosemide or equivalent dose.
* Daily urea, creatinine and eGFR.
* Blood sugar monitoring.
J. Follow-up visits:
Patients will be followed in the outpatient clinic at 2 months after discharge, with the following data to be obtained:
1. NYHA class, and occurrence of any cardiac symptoms.
2. Need and reason for re-hospitalization.
3. History of dysuria, or genital discharge.
4. Medication intake and compliance.
5. Clinical examination including vital signs, body weight, and signs of left or right side HF.
6. Urea, creatinine and eGFR.
7. Electrolytes including Na and K.
8. HbA1C.
K. Follow-up serum NT-proBNP:
* At 2 months after discharge.
* Data will be compared to baseline values.
In case of mortality, data will be collected about the date and cause of mortality, and any reported clinical events before mortality.
* Potential risks:
1. Mild pain during blood sample withdrawal.
2. Low incidence of occurrence of side effects for Dapagliflozin including urinary tract infection, hypotension, and in rare cases hypoglycemia or metabolic acidosis.
* Confidentiality of data:
Data will be presented and used without inference to the name or personal data of the patients. All patient records will be handelled in accordance to hospital and national confidentiality protocols.
\- Sample size :
Based on the results mentioned in a previously published similar study, where the frequency of composite endpoint of worsening HF, rehospitalization for HF or death at 60 days was 10% in the Empagliflozin group versus 33% in the placebo group, with a study power of 80% and a significance level of 5%, and by using an online sample size calculator (http://statulator.com/SampleSize/ss2P.html), the estimated sample size is 55 patients per group.
\- Statistical analysis
Descriptive statistics will be summarized as mean ± SD for normally distributed continuous variables or otherwise as median and 25th to 75th percentile. Categorical variables will be described by frequencies and percentages. Differences in paired samples will be tested using the Wilcoxon signed-rank test or paired Student's t-test. Categorical variables will be compared using the chi-square or Fisher's exact test. Statistical significance is defined at a level of α ≤ 0.05.
Kaplan-Meier survival curves will be drawn to assess differences between groups for the time to an event. For the Cox model, univariate analysis of each of the possible predictors of the outcome will be tested, and only those variables that are significant at P\<0.05 will be included in a multivariable model. A stepwise option will be used to determine independent predictors of the outcome variables.
Analysis will be performed with SPSS, Version 24 (SPSS Inc., Chicago, IL, USA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dapagliflozin group
This group will receive oral Dapagliflozin 10 mg once daily within 24 hours from hospital admission, in addition to the standard treatment for acute heart failure.
Group Type
EXPERIMENTAL
Dapagliflozin 10mg Tab
Intervention Type
DRUG
Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
Standard group
This group will only receive the standard treatment for acute heart failure.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapagliflozin 10mg Tab
Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Sodium-glucose cotransporter-2 inhibitors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients above 18 years presenting with acute heart failure defined as rapid development of dyspnea NYHA class III-IV associated with clinical signs of HF (e.g. congested neck veins, pulmonary rales, lower limb swelling, radiological evidence of pulmonary congestion) with LVEF ≤ 40%.
Exclusion Criteria
1. Cardiogenic shock on admission, defined as SBP \< 90 mmHg plus signs of peripheral hypoperfusion or the need of vasopressor or inotropic support.
2. Estimated GFR \< 30 mL/min/1.73 m2.
3. Pregnancy or lactation.
4. Type I DM or history of DKA.
5. Treatment with any SGLT2 inhibitor in the last month.
6. Known intolerance to any SGLT2 inhibitor.
7. Severe anemia (Hemoglobin \< 7 g/dl).
2. Estimated GFR \< 30 mL/min/1.73 m2.
3. Pregnancy or lactation.
4. Type I DM or history of DKA.
5. Treatment with any SGLT2 inhibitor in the last month.
6. Known intolerance to any SGLT2 inhibitor.
7. Severe anemia (Hemoglobin \< 7 g/dl).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aswan Heart Centre
OTHER
Sponsor Role
collaborator
Cairo University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hossameldin Elsayed Khalifa Hussein
Assistant Lecturer of Cardiology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Magdy Abdelhamid, Professor
Role: PRINCIPAL_INVESTIGATOR
Chairman of Cardiology Department, Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan Heart Centre
Aswān, , Egypt
Site Status
Kasr Al-Ainy Medical School
Cairo, , Egypt
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Egypt
References
Explore related publications, articles, or registry entries linked to this study.
Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020 Apr;22(4):713-722. doi: 10.1002/ejhf.1713. Epub 2020 Jan 7.
Reference Type
BACKGROUND
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
Reference Type
BACKGROUND
Ul Amin N, Sabir F, Amin T, Sarfraz Z, Sarfraz A, Robles-Velasco K, Cherrez-Ojeda I. SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Healthcare (Basel). 2022 Nov 23;10(12):2356. doi: 10.3390/healthcare10122356.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD-343-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction
NCT05420285
UNKNOWN
PHASE2
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
NCT04249778
COMPLETED
PHASE4
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124
COMPLETED
PHASE3
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
NCT04564742
COMPLETED
PHASE3
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
NCT06065280
COMPLETED
NA
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
NCT03877237
COMPLETED
PHASE3
Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)
NCT05406505
COMPLETED
PHASE2/PHASE3
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
NCT03619213
COMPLETED
PHASE3
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
NCT04782245
WITHDRAWN
PHASE2
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
NCT04475042
UNKNOWN
PHASE2
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675
COMPLETED
PHASE4
Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial
NCT00937092
UNKNOWN
PHASE4
Dapagliflozin With or Without Spironolactone for HFpEF
NCT05676684
COMPLETED
PHASE2/PHASE3
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
NCT04956809
COMPLETED
PHASE2
Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
NCT06510270
NOT_YET_RECRUITING
NA
Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF
NCT04197635
COMPLETED
PHASE4
Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
NCT06721442
COMPLETED
PHASE4
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
NCT05764057
RECRUITING
PHASE3
Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure
NCT05770167
UNKNOWN
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
NCT06783166
RECRUITING
PHASE2/PHASE3
Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
NCT04707352
COMPLETED
PHASE3
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
NCT04304560
UNKNOWN
PHASE2
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
RECRUITING
PHASE3